Skip to content

US · CLYM · BIOTECHNOLOGY

Climb Bio, Inc. (CLYM) intrinsic value and stock valuation

$9.19as of 2026-11-21 · Mkt cap 850.26M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Climb Bio, Inc. DCF and intrinsic value

InvestorsCraft values CLYM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CLYM’s statements →

Climb Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Wellesley Hills, MA 02481 climbbio.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-59.85M
20192025
Free cash flow
-$-54.54M
20192025
Total equity
$160.5M+49.4% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-67.88M-$-82.02M-$-40.27M-$-45.13M-$-35.67M
Net income-$-59.85M-$-73.9M-$-35.12M-$-45.24M-$-47.48M
EPSd-$-882.61K-$-1.53M-$-1.3M-$-1.72M-$-3.87M
Operating cash flow-$-54.36M-$-15.56M-$-20.6M-$-37.37M-$-36.07M
Capital expenditure-$-190K$0.00$0.00$0.00$0.00
Free cash flow-$-54.54M-$-15.56M-$-20.6M-$-37.37M-$-36.07M
Total assets$167.7M$217.2M$110.5M$135M$173.2M
Total debt$540K$530K$350K$480K$0.00
Net debt-$-35.14M-$-86.7M-$-92.76M-$-43.1M-$-46.92M
Total equity$160.5M$211.9M$107.6M$128.7M$167.2M
Cash and short-term investments$101.1M$150.9M$106.8M$123.6M$136.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$100K$0.00$0.00$0.00$0.00
Gross profit-$-100K$0.00$0.00$0.00$0.00
Research and development expenses$46.6M$14.3M$15.4M$26.2M$23.3M
Selling, general and administrative expenses$21.2M$16M$24.9M$18.9M$12.4M
Other expenses$0.00$51.7M$0.00$0.00$0.00
Operating expenses$67.8M$82M$40.3M$45.1M$35.7M
Cost and expenses$67.9M$82M$40.3M$45.1M$35.7M
Interest income$8.32M$8.13M$4.62M$1.38M$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$100K$0.00$0.00$0.00$0.00
Ebitda-$-59.75M-$-30.36M-$-35.12M-$-45.24M-$-47.48M
Operating income-$-67.88M-$-82.02M-$-40.27M-$-45.13M-$-35.67M
Total other income/expenses, net$8.03M$8.12M$5.16M-$-110K-$-11.81M
Income before tax-$-59.85M-$-73.9M-$-35.12M-$-45.24M-$-47.48M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-59.85M-$-73.9M-$-35.12M-$-45.24M-$-47.48M
Weighted average shares outstanding$67.8M$48.2M$27M$26.3M$12.3M
Weighted average diluted shares outstanding$67.8M$48.2M$27M$26.3M$12.3M
Balance sheet
20252024202320222021
Cash and short-term investments$101.1M$150.9M$106.8M$123.6M$136.5M
Net receivables$0.00$1.12M$2.46M$6.49M$6.52M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$105.9M$154.9M$110.3M$134.4M$148.3M
Property, plant and equipment, net$790K$490K$200K$470K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$59.6M$61.6M$0.00$0.00$24.9M
Total non-current assets$61.9M$62.3M$210K$600K$25M
Total assets$167.7M$217.2M$110.5M$135M$173.2M
Accounts payable$2.27M$700K$70K$750K$1.4M
Short-term debt$260K$160K$330K$300K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.98M$4.93M$2.83M$6.1M$6.03M
Long-term debt$280K$380K$10K$180K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$280K$380K$40K$180K$10K
Capital lease obligations$280K$530K$350K$480K$0.00
Total liabilities$7.27M$5.31M$2.87M$6.28M$6.04M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-289.73M-$-229.88M-$-155.98M-$-120.86M-$-75.62M
Accumulated other comprehensive income (loss)$430K$20K-$0.00-$-360K-$-120K
Total equity$160.5M$211.9M$107.6M$128.7M$167.2M
Total investments$125M$125.3M$13.7M$80M$114.5M
Total debt$540K$530K$350K$480K$0.00
Net debt-$-35.14M-$-86.7M-$-92.76M-$-43.1M-$-46.92M
Cash flow statement
20252024202320222021
Net income-$-59.85M-$-73.9M-$-35.12M-$-45.24M-$-47.48M
Depreciation and amortization$100K$0.00$0.00$0.00$0.00
Stock-based compensation$8.05M$5.56M$12.8M$6.99M$3.74M
Change in working capital-$-600K$1.7M$3.76M$210K-$-4.17M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.56M-$-1.14M-$-690K-$-650K$320K
Net cash provided by operating activities-$-54.36M-$-15.56M-$-20.6M-$-37.37M-$-36.07M
Investments in property, plant and equipment-$-190K$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$2.83M-$-121.09M$69M$34.4M-$-114.97M
Common stock issued-$-20K$119.8M$840K$0.00$83.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-20K$130.7M$840K$0.00$177.2M
Net change in cash-$-51.54M-$-5.88M$49.5M-$-3.34M$26.4M
Cash at end of period$35.7M$87.2M$93.1M$43.6M$46.9M
Operating cash flow-$-54.36M-$-15.56M-$-20.6M-$-37.37M-$-36.07M
Capital expenditure-$-190K$0.00$0.00$0.00$0.00
Free cash flow-$-54.54M-$-15.56M-$-20.6M-$-37.37M-$-36.07M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Climb Bio, Inc.

        Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

        CEO
        Aoife Brennan BCh MMSc
        Employees
        28
        Beta
        0.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Climb Bio, Inc. (CLYM)?

        InvestorsCraft does not currently publish an intrinsic value for CLYM. How the IC value is calculated.

        Is CLYM undervalued?

        InvestorsCraft does not publish an undervaluation signal for CLYM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.